The prognostic value of ultrasound features and parafibromin expression in parathyroid carcinoma
Open Access
- 4 March 2025
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-7
Abstract
Objectives: To investigate prognostic factors related with parathyroid carcinoma (PC) based upon ultrasound (US) parameters and parafibromin expression. Methods: Between 2000/01 and 2022/07, thirty-four PC patients with detailed preoperative ultrasonography were enrolled in the research. Immunohistochemical staining of parafibromin was performed on pathological samples of these patients. Based on the expression of parafibromin, the cases were divided into a positive control group (parafibromin expression ≥ 10%) and a negative experimental group (parafibromin expression < 10%). The ultrasound and clinical features of the two groups were analyzed, and Cox regression was used to identify the independent prognostic factors regarding disease-free survival (DFS) and overall survival (OS). Results: Among 34 patients with parathyroid carcinoma, 26 (76.5%) were parafibromin-positive, while 8 (23.5%) were parafibromin-negative. The mean follow-up time was 72.6 (11.0-179.3) months. During the overall survival period, 7 cases (20.6%) died, and 9 cases (26.5%) experienced recurrence or metastasis. The median overall survival time (interquartile range) was 65.7 (35.5–89.7) months, and the median disease-free survival time (interquartile range) was 38.2 (22.2–69.7) months. The risk of recurrence and metastasis in the parafibromin-negative group was 5.9 times higher than that in parafibromin-positive group (95% CI 1.569–22.190). PC patients with calcification on preoperative ultrasonography had a 9.4 times higher risk of death during the overall survival period compared with patients without calcification (95% CI 1.037–85.915). However, parafibromin expression did not show a significant impact on the prognosis of the overall survival. Conclusions: Preoperative US-detected calcification within the lesion is an independent risk factor indicating the shorter OS for PC patients, while loss of parafibromin expression is significant for indicating the recurrence or metastasis of PC patients.Keywords
Funding Information
- National High Level Hospital Clinical Research Funding (2022-PUMCH-B-066)
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2023- I2M-2-002)
- Sanming Project of Medicine in Shenzen Municipality (SZSM202111011)
This publication has 30 references indexed in Scilit:
- HypercalcemiaJAMA, 2022
- Multiple Pathways for Pathological Calcification in the Human BodyAdvanced Healthcare Materials, 2020
- The association between mammographic calcifications and breast cancer prognostic factors in a population‐based registry cohortCancer, 2016
- Trends in the incidence and treatment of parathyroid cancer in the United StatesCancer, 2007
- Mammographic tumor features can predict long‐term outcomes reliably in women with 1–14‐mm invasive breast carcinomaCancer, 2004
- Parathyroid carcinoma: A 22‐year experienceHead & Neck, 2004
- Calcium hydroxyapatite promotes mitogenesis and matrix metalloproteinase expression in human breast cancer cell linesMolecular Carcinogenesis, 2001
- Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995Cancer, 1999
- Diagnosis and treatment of patients with parathyroid carcinoma: An update and reviewWorld Journal of Surgery, 1991
- Microradiographic investigations of calcifications of the female breastCancer, 1969